Solara Active Pharma Sciences Grants 25,000 Stock Options to Employees

Solara Active Pharma Sciences Limited, a prominent player in the pharmaceutical industry, has announced an employee incentive program. The company's Board of Directors has approved the grant of 25,000 stock options to eligible employees under the Solara Employee Stock Option Plan 2024.

Key Details of the Stock Option Grant

Number of Options: 25,000 stock options
Exercise Price: Rs. 375 per equity share
Vesting Schedule:

Year Percentage of Options Vested

First Year 20%

Second Year 30%

Third Year 50%
Minimum Vesting Period: One year from the grant date
Exercise Period: 120 days from the date of vesting

Year	Percentage of Options Vested
First Year	20%
Second Year	30%
Third Year	50%

This move by Solara Active Pharma Sciences is aimed at aligning employee interests with those of the company and its shareholders. The stock option plan serves as a long-term incentive, potentially enhancing employee retention and motivation.

Vesting and Exercise Details

The vesting of the options will occur over a three-year period, with a minimum vesting period of one year from the grant date. This gradual vesting schedule encourages long-term commitment from employees while also providing them with the opportunity to benefit from the company's potential growth.

Once vested, employees will have a window of 120 days to exercise their options. This exercise period allows employees to make informed decisions based on market conditions and personal financial planning.

Implications for Solara and Its Employees

For Solara Active Pharma Sciences, this stock option grant represents a strategic approach to talent management and retention. By offering equity participation, the company is fostering a sense of ownership among its workforce, which may lead to increased productivity and alignment with corporate goals.

For eligible employees, these stock options present an opportunity to participate in the company's financial success. The exercise price of Rs. 375 per share sets a clear benchmark for potential gains, should the company's stock price appreciate over time.

As Solara Active Pharma Sciences continues to navigate the competitive pharmaceutical landscape, this employee stock option plan may play a role in attracting and retaining talent, which is often important in driving innovation and growth in the pharmaceutical sector.

Solara Active Pharma Sciences - PP , a prominent player in the pharmaceutical industry, has announced significant changes to its board composition, committee structure, and organizational roles. The company disclosed these developments in regulatory filings.

Key Highlights

Director Resignation: Mr. Kartheek Chintalapati Raju has stepped down from his position as Non-Executive Director, effective November 5, 2025.
Reason for Departure: The resignation is attributed to preoccupation and personal commitments.
Committee Changes: Mr. Raju's departure also affects his roles in the Stakeholders Relationship Committee and Nomination and Remuneration Committee.
Board Restructuring: The company's Board of Directors has reconstituted both committees following the resignation.
New Appointments and Role Changes: The Board approved several organizational changes, including new appointments and role expansions.
New CHRO Appointment: Mohanraj S has been appointed as Chief Human Resources Officer and designated as Senior Management Personnel.

Reconstituted Committees

Stakeholders Relationship Committee

Position	Name	Role
Chairperson	Dr. Kausalya Santhanam	Independent Director
Member	Mr. Sandeep Shashikantha Rao	Executive Director
Member	Mr. Manish Gupta	Non-Executive Director

Nomination and Remuneration Committee

Position	Name	Role
Chairperson	Mr. Rajendra Kumar Srivastava	Independent Director
Member	Dr. Kausalya Santhanam	Independent Director
Member	Mr. R Ramakrishnan	Independent Director
Member	Mr. Rajiv Vijay Nabar	Independent Director

Organizational Changes

Chief Investor Relations Officer: Sarat Kumar Asuri, the current Chief Financial Officer, has been appointed to the additional role of Chief Investor Relations Officer.
Remuneration Revision: The board revised the remuneration of Whole-time Director Mohan Muthunarayanan within previously approved shareholder limits.
Senior Management Compensation: The company updated compensation for eligible Senior Management Personnel.
Risk Management: The existing Risk Management Policy was reviewed and confirmed.
Chief Human Resources Officer: Mohanraj S has been appointed as Chief Human Resources Officer and designated as Senior Management Personnel, effective November 5, 2025.

New CHRO Profile

Mohanraj S brings over 30 years of cross-industry experience to his new role as Chief Human Resources Officer. His expertise spans various sectors including Pharma, Biotech, Engineering, Aerospace, Apparel, and Media. Mohanraj's areas of specialization include:

Talent Management
Employee Relations
Organizational Development
HRIS
Digital Transformation

Prior to joining Solara Active Pharma Sciences - PP, Mohanraj held HR leadership positions at notable organizations such as Mylan Laboratories, The Manipal Group, and Tata Advanced Materials. His educational background includes:

Masters in Social Work (HRM) from Madras University
BA in Behavioural Sciences from St. Josephs College, Bangalore

Additionally, Mohanraj is a certified ISO auditor and has served on the Board of Studies for Industrial Relations at St. Josephs University for two decades.

The company expressed its appreciation for Mr. Raju's contributions during his tenure, acknowledging the value of his experience and guidance to Solara Active Pharma Sciences - PP.

These changes in the board structure, committee compositions, and organizational roles are expected to ensure continued strong governance and oversight at Solara Active Pharma Sciences - PP. The company remains committed to maintaining high standards of corporate governance and adapting its leadership structure to meet evolving business needs.